The concept of immunoediting posits that the enhanced immunity afforded by anti-PD1/PDL1 therapy safeguards the host against tumor progression and engenders the emergence of tumor subclones that can evade antitumor immunity, precipitating acquired resistance to anti-PD1/PDL1 therapy [194,332,333]. The gene discussed is PDCD1; the disease is neoplasm.